Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000912 · ClinicalTrials.gov registry record · Phase 2
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 475
- Enrollment target
NCT00000912: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000912 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 475 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (257% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000912, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 475 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment. This study evaluates the safety of these drug combinations, which include an experimental protease inhibitor (PI), amprenavir. Despite the success that many patients have had with PI treatment regimens, there is still a possibility that patients receiving PIs may continue to have high HIV blood levels. Because of this possibility, alternative drug combinations containing PIs are being studied. It appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in patients with prior PI treatment experience.
Interventions
- DRUG Efavirenz
- DRUG Indinavir sulfate
- DRUG Nelfinavir mesylate
- DRUG Abacavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Est. Completion | 2000-05 |
| Phase | Phase 2 |
What the finished NCT00000912 record still lists
NCT00000912 is an interventional study that assigns participants to a tested intervention. The registered 475 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (257% higher).
The record links to 0 conditions, and to 5 interventions - of which Efavirenz is the first listed.
NCT00000912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000912 about?
NCT00000912 is a clinical study titled "A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients". The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment. This study evaluates the safety of these drug combinations, which include an experimental protease...
What is the current status of trial NCT00000912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 475 participants. Estimated completion is 2000-05.
What interventions are being tested in trial NCT00000912?
The interventions under investigation include: Efavirenz (DRUG), Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00000912?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000912's enrollment target sits among peer trials
475 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- NCT05451303 · 475 participants
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
- NCT06892379 · 475 participants · Phase 1
A Study of HS-20110 in Participants With Advanced Solid Tumors
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)